HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase ...

Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase ...

Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells No significant financial relationships to disclose. This is an ASCO ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...